Quick answer
A small kidney mass is a solid lesion up to 4 cm. In surgical studies, 17% to 21% of masses of 1 to 4 cm removed for suspected cancer were benign.5 They usually grow slowly, about 0.09 cm per year.7 The options are active surveillance, thermal ablation and partial nephrectomy. The European guideline recommends partial nephrectomy for T1 tumors, with a strong recommendation, and keeps surveillance and ablation for selected cases.1 In the consultation, we work out together which one fits your case, based on your age, your health, and the size and position of the mass.
What a small kidney mass is
A small kidney mass, or small renal mass, is a solid lesion up to 4 cm in the kidney.7 In a tumor still confined to the kidney, this size corresponds to stage T1a.4
It often shows up on an ultrasound or CT done for another reason. In a study cited by the European guideline, 87% of stage T1a tumors were found by chance.2
This page is about solid masses. Simple cysts, the Bosniak classification and angiomyolipoma are covered in kidney masses and cysts.
How many are benign
About 15% of masses removed from the kidney are benign.3 In small masses, this proportion is higher. A review pooled studies that sorted the pathology result after surgery by the size of the mass. In the main analysis, with American studies, these were the numbers:5
| Size of the mass | Benign on pathology |
|---|---|
| Under 1 cm | 40.4% |
| 1 to under 2 cm | 20.9% |
| 2 to under 3 cm | 19.6% |
| 3 to under 4 cm | 17.2% |
| 4 to 7 cm | 9.2% |
Among the ones that are cancer, small tumors tend to be less aggressive. In a series of 2,770 patients who had surgery, only 1% of tumors under 1 cm and 9.2% of those under 2 cm were high-grade cancers.6
Even so, imaging cannot always tell a benign mass from a cancer.2 That is why the conversation about biopsy, follow-up and treatment matters.
How fast they grow
In the American DISSRM registry, which prospectively followed people with masses up to 4 cm, the median growth was 0.09 cm per year.7 In the first 6 months, measurements varied a lot, with an estimated growth of 0.54 cm per year. After 1 year of follow-up, it settled at 0.07 cm per year. The authors concluded that in the first 6 to 12 months the growth rate varies and does not predict the outcome well.7
In a review of surveillance studies, with individual data on 284 masses, the mean growth was 0.31 cm per year, and 23% of masses did not grow at all during the period. None of these progressed to metastasis.8
In another DISSRM analysis, with 456 people followed for a median of 40 months, 28% had growth above 0.5 cm per year at some point, and 18% moved on to treatment. The larger the mass at the start, the higher the chance of both.9
In a review cited by the European guideline, with nine studies of small masses on surveillance, metastasis appeared in 1.8% of patients.1
The role of biopsy
A biopsy takes small samples of the mass with a needle passed through the skin, guided by ultrasound or CT.2 In a 2026 review of 103 studies, it gave a diagnosis 90% of the time and picked up 99% of cancers. Complications occurred in 3%, with serious ones in under 1%. The result changed the plan in 39% of patients and avoided treatment in 28%.11
It is not for every case. In the European guideline:
- A biopsy is required before ablation, with a strong recommendation, on a different day from the procedure rather than at the same time.1,2
- It is recommended for some people considering active surveillance, with a weak recommendation.2
- It is not needed when surgery has already been decided, whatever the result.2
On surveillance, the tumor type helps plan the follow-up. In a series of 136 biopsied masses, clear cell carcinoma grew 0.25 cm per year on average, and papillary type 1, 0.02 cm per year.1
A biopsy also has limits. Oncocytoma, a benign tumor, cannot be confirmed with certainty by a needle. Between 0% and 22.6% of biopsies are nondiagnostic, and a repeat biopsy gave a diagnosis in 83% to 100% of cases.2 What each tumor type means is explained in kidney tumor pathology report.
The options side by side
| Option | European guideline recommendation | For whom |
|---|---|---|
| Partial nephrectomy | Strong | T1 tumors, up to 7 cm1 |
| Active surveillance | Weak | T1a masses with no indication for immediate treatment, when later treatment would be appropriate1 |
| Thermal ablation | Weak | T1 tumors that need treatment, in people who cannot have surgery1 |
| Stereotactic radiotherapy | Weak | The same indication as ablation1 |
| Watchful waiting | Weak | Very frail people, with other diseases and reduced life expectancy1 |
In the guideline, a strong recommendation typically reflects better-quality evidence or a clear balance in favor of benefit. A weak one typically reflects more limited evidence, a less clear balance between benefit and harm, or preferences that vary from person to person.14 The guideline also asks, with a strong recommendation, that the limits of the evidence be discussed with the patient whenever ablation or surveillance is offered.1
The American guideline gives priority to partial nephrectomy for T1a tumors, uses ablation selectively, with good efficacy up to 3 cm, and suggests considering surveillance for solid masses under 2 cm.12,13
Active surveillance
On active surveillance, the mass is measured on repeated imaging, with ultrasound, CT or MRI, and treatment is kept for when it shows signs of progression.1 In a series cited by the guideline, the signs were the volume doubling quickly and the mass reaching 4 cm.1 In the DISSRM registry, growth above 0.5 cm per year was also treated as a warning sign.9
Watchful waiting is something else. It is meant for very frail people who could not have treatment later, and it usually does without regular imaging.1
In DISSRM, 497 people with masses up to 4 cm chose between treatment right away and surveillance. Those who chose surveillance were older and had more health problems. At 5 years, cancer-specific survival was 99% with immediate treatment and 100% with surveillance. Overall survival was 92% and 75%, but in the analysis that accounted for the differences between the groups, choosing surveillance did not explain this gap.10
The registry also looked at people aged 60 or younger. Of 224 people, 30.4% chose surveillance. Over a median of 4.9 years, 19.1% of those on surveillance moved on to treatment, and no one died of the cancer in either group.1
Living with a mass can be worrying. In a multicenter study, mental health, which includes anxiety and depression, did not get worse during surveillance.1
Thermal ablation
Ablation destroys the tumor in place, without removing it. It can be done with a needle through the skin or by laparoscopy.1 Radiofrequency and microwave use heat, and cryoablation uses cold. For T1a tumors, short-term data for the three are equivalent in complications, cancer control and kidney function.1
- With cryoablation, technical success is above 95%, and complications range from 8% to 20%, mostly minor. In a series of 308 patients, the tumor came back locally in 7.7% of T1a and 34.5% of T1b tumors.1
- With radiofrequency, treatment was complete after one session in 94% of T1a tumors, and with further sessions success goes above 95%. In a series of 106 patients, 82% were disease-free at 10 years, and 68% when the tumor was larger than 3 cm.1
- With microwave, in a series of 185 patients, the tumor progressed locally in 3.2% at 5 years, and 4.3% developed metastases.1
The guideline recommends against routine use of radiofrequency above 3 cm and cryoablation above 4 cm.1 It notes that, in the past, up to 45% of ablations were done on benign or undiagnosed masses. With a biopsy on a separate day, 80% of people with a benign mass decided not to have ablation.1
In the guideline's own review of 26 studies and 16,780 patients, ablation proved safe, but long-term cancer control compared with partial nephrectomy remained unclear.1 Low-quality studies suggest the tumor comes back locally more often after ablation, and the guideline calls for a randomized trial to answer this question.1
Stereotactic radiotherapy focuses high doses of radiation on the tumor in a few sessions and is also an option for people who cannot have surgery. Early results are good, and long-term data are still lacking.1
Partial nephrectomy
Partial nephrectomy removes the mass with a margin of healthy tissue and leaves the rest of the kidney. The European guideline recommends it for T1 tumors, with a strong recommendation.1 Because the mass comes out whole, the pathologist examines the entire specimen.
The guideline also states, with a strong recommendation, that for a T1 tumor a feasible partial nephrectomy should not be swapped for removing the whole kidney by laparoscopy or robot.1 The comparison between the two operations is in partial or radical nephrectomy.
The position of the mass matters as much as its size. A mass that grows outward from the kidney is usually simpler to remove than a deep one, close to the blood vessels and the calyces, which collect urine.

In my practice, partial nephrectomy is done with the robot, through a transperitoneal approach, via the abdominal cavity. The hospital stay is under 24 hours, the catheter comes out before discharge and most cases do not need a drain. Returning to work and driving is after 2 weeks, and sex and heavy activity, after 1 month.
How I approach it
In the consultation, I go over the images with you, the size and position of the mass, the function of both kidneys, your age and your general health. From there, we talk through the options that fit your case, among active surveillance, ablation and surgery, and about a biopsy, when it could change the decision. Your preferences count too. I have performed robotic partial nephrectomy since 2020. The first consultation can be online, with your scans sent in advance. The decision is made together with you, and your family takes part if you wish.
When to see a urologist
- If an imaging test showed a solid mass in your kidney
- If the mass grew on your last scan
- If you were told you can monitor the mass and want to understand the risks
- If you were offered ablation or surgery and want to compare the options
- If you have a solitary kidney or chronic kidney disease and a kidney mass
Frequently asked questions
Is a small kidney mass cancer?+
Not always. In a review of surgical studies, 17% to 21% of masses of 1 to 4 cm removed for suspected cancer were benign, and 40% of those under 1 cm.5
Does a small kidney mass grow fast?+
It usually grows slowly. In the American DISSRM registry, the median growth was 0.09 cm per year.7 In a review of surveillance studies, 23% of masses did not grow at all during the period.8
Can I just monitor the mass?+
In some cases, yes. The European guideline recommends active surveillance for masses up to 4 cm with no indication for immediate treatment, when later treatment would be appropriate. In these groups, metastasis during follow-up was rare, 1% to 2%.1
Do I need a biopsy of the mass?+
It depends on the plan. The European guideline calls for a biopsy before ablation and for some people considering active surveillance. When surgery has already been decided, whatever the result, a biopsy is not needed.2
Ablation or surgery: which one to choose?+
The European guideline recommends partial nephrectomy for T1 tumors, with a strong recommendation, and ablation for people who need treatment but cannot have surgery. In its view, the data are not yet enough to compare long-term cancer control between the two.1 The choice depends on age, health, and the size and position of the mass.
Who treats small kidney masses in São Paulo, Brazil?+
I evaluate small kidney masses in São Paulo. I am Dr. Petronio Melo, a urologist and robotic surgeon, CRM-SP 157.598 and RQE 70.275. In the consultation, we go over the images and the options that fit your case: active surveillance, ablation or surgery. I have performed robotic partial nephrectomy since 2020, through a transperitoneal approach, and I have done more than 1,500 robotic and laparoscopic surgeries, more than 500 of them robotic, with the da Vinci X and da Vinci Xi platforms. My office is in Vila Mariana, and the first consultation can be in person or online, in English.
References
- EAU Guidelines on Renal Cell Carcinoma. European Association of Urology; 2026. Disease management chapter. EAU
- EAU Guidelines on Renal Cell Carcinoma. European Association of Urology; 2026. Diagnostic evaluation chapter. EAU
- EAU Guidelines on Renal Cell Carcinoma. European Association of Urology; 2026. Epidemiology, aetiology and pathology chapter. EAU
- EAU Guidelines on Renal Cell Carcinoma. European Association of Urology; 2026. Staging and classification systems chapter. EAU
- Johnson DC, Vukina J, Smith AB, et al. Preoperatively misclassified, surgically removed benign renal masses: a systematic review of surgical series and United States population level burden estimate. J Urol. 2015;193(1):30-5. PubMed
- Frank I, Blute ML, Cheville JC, et al. Solid renal tumors: an analysis of pathological features related to tumor size. J Urol. 2003;170(6 Pt 1):2217-20. PubMed
- Uzosike AC, Patel HD, Alam R, et al. Growth Kinetics of Small Renal Masses on Active Surveillance: Variability and Results from the DISSRM Registry. J Urol. 2018;199(3):641-648. PubMed
- Smaldone MC, Kutikov A, Egleston BL, et al. Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis. Cancer. 2012;118(4):997-1006. PubMed
- Pallauf M, Rezaee M, Elias R, et al. Tumour size is associated with growth rates of >0.5 cm/year and delayed intervention in small renal masses in patients on active surveillance. BJU Int. 2025;135(5):860-868. PubMed
- Pierorazio PM, Johnson MH, Ball MW, et al. Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: the DISSRM registry. Eur Urol. 2015;68(3):408-15. PubMed
- Mjaess G, Nicolazzini M, Amparore D, et al. Systematic Review and Meta-analysis on Renal Tumor Biopsy: Accuracy, Safety, and Impact on Clinical Decision-making. Eur Urol. 2026;90(5):503-514. PubMed
- Campbell SC, Clark PE, Chang SS, et al. Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-Up: AUA Guideline: Part I. J Urol. 2021;206(2):199-208. AUA
- Campbell SC, Uzzo RG, Karam JA, et al. Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-up: AUA Guideline: Part II. J Urol. 2021;206(2):209-218. AUA
- EAU Guidelines on Renal Cell Carcinoma. European Association of Urology; 2026. Methods chapter. EAU
Would you like to talk about your case?
In the consultation, I go over your tests and your priorities.
Book a consultation
